ULC0454T_S39
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.520
- INTERFERON_GAMMA_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- KRAS_SIGNALING_DN+0.250
- COMPLEMENT+0.130
- IL6_JAK_STAT3_SIGNALING+0.130
- KRAS_SIGNALING_UP+0.130
- WNT_BETA_CATENIN_SIGNALING+0.120
- P53_PATHWAY+0.110
Top 10 suppressed
- PROTEIN_SECRETION-0.510
- MTORC1_SIGNALING-0.410
- ADIPOGENESIS-0.390
- OXIDATIVE_PHOSPHORYLATION-0.390
- FATTY_ACID_METABOLISM-0.370
- CHOLESTEROL_HOMEOSTASIS-0.340
- XENOBIOTIC_METABOLISM-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- BILE_ACID_METABOLISM-0.280
- MYC_TARGETS_V1-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-90-A59Q-01A-11R-A26W-07 | — | cohortA1 | 0.882 |
| 2 | TCGA-93-A4JQ-01A-11R-A24X-07 | — | cohortA1 | 0.857 |
| 3 | X0e8b5ba7.3bee.4627.a8b6.f94263f78e3e | — | cohortMD2 | 0.849 |
| 4 | TCGA-55-A48Z-01A-12R-A24X-07 | — | cohortA1 | 0.849 |
| 5 | TCGA-AQ-A7U7-01A-22R-A352-07 | — | D | 0.846 |
| 6 | MNG1248 | — | — | 0.832 |
| 7 | MNG537 | — | — | 0.830 |
| 8 | MNG548 | — | — | 0.826 |
| 9 | SRR8942969 | — | — | 0.824 |
| 10 | SRR12202486 | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |